The Antibacterial Resistance Leadership Group (ARLG) seeks proposals for clinical studies (e.g., randomized controlled trials, case-control studies or cohort studies) to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. Ideal studies: 1) have the potential to transform medical practice and 2) would be unlikely to occur without ARLG support. Applications that propose pre-clinical or non-clinical research, studies of non-bacterial pathogens, or research not directly related to antibiotic resistance will be considered non-responsive. Studies of pharmacokinetics, pharmacodynamics or studies in selected populations (e.g., immunocompromised hosts, patients in long-term care settings, neonates, overweight or obese children) are encouraged. Intensive budget constraints require focused prioritization of applications and their feasibility.
The ARLG has prioritized four areas of research and is currently soliciting clinical studies to:
Infections Caused by Gram-negative Bacteria
- Develop and test antimicrobial agents or strategies for Gram-negative infections in adults or children caused by multiple-drug resistance gram-negative bacilli including carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant bacteria.
- Evaluate novel agents or strategies to prevent emergence of resistance during treatment of infections caused by Gram-negative bacilli.
- Optimize administration of antimicrobial agents for treatment of Gram-negative infections with respect to dose, dosing interval, and duration of therapy in adults or children.
Infections Caused by Gram-positive Bacteria
- Investigate strategies or therapies, including narrow-spectrum oral antimicrobials, for treatment of infections predominantly caused by Gram-positive bacteria, including skin and soft tissue infections, bone and joint infections, and bacteremia in adults and children.
- Compare the effectiveness of linezolid and daptomycin or other antibiotics alone or in combination with other agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin resistant enterococci (VRE).
- Optimize administration of antimicrobial agents for treatment of Gram-positive infections with respect to dose, dosing interval, and duration of therapy in adults or children.
- Assess antibacterial stewardship strategies for non-use or early discontinuation of antibacterial therapy to reduce emergence and spread of antibiotic resistant bacteria.
- Evaluate transmission dynamics or emergence of carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant Gram-negative bacilli in healthcare and community settings.
- Examine strategies (e.g., stewardship, decolonization, probiotics) to prevent occurrence or recurrence or reduce the risk of resistant Gram-negatives, Clostridium difficile infection, VRE, or MRSA.
- Evaluate methods or platforms, which may include biomarkers or host-response markers (e.g., “omics”) to rapidly identify bacterial pathogens and infections. Approaches could include simple and rapid point-of-care diagnostics to detect drug resistance, guide antibacterial therapy, or support clinical trials.
- Evaluate rapid, accurate methods for antimicrobial susceptibility testing of cultured bacteria.